Showing all 8 results




    5f adb Pinaca is a cannabinoid that is found in some products that are based on cannabis. It is a strong agonist for both the CB1 and CB2 receptors, with EC50 values of 0.24 nM for the CB1 receptor and 2.1 nM for the CB2 receptor.






  • 5f akb48

    5f akb48


    5f AKB48 – Professional chemists often use a compound called 5f-AKB48. The compound was made to replace the chemical AKB-48. This makes AKB 57 a more refined version of that chemical that works better and is easier to plan for.




  • 5f sgt 151

    5f sgt 151


    5-fluoropentyl-2-(1-methyl-1-phenyl-ethyl)-2,5-dihydro-pyrido[4,3-b]indol-1-one, also known as 5f SGT 151 or 5F-CUMYL-PeGaCLONE, is one of the new generation of novel synthetic cannabinoids that is currently uncontrolled in most of the EU for use in laboratory research.



  • FUB-AKB48



    FUB-APINACA (also known as AFUBINACA and FUB-AKB48) is an indazole-based synthetic cannabinoid that has been sold online as a designer drug and is thought to be a potent agonist of the CB1 receptor.

    [1] It is an APINACA and 5F-APINACA analog in which the pentyl chain has been replaced with fluorobenzyl.




    AMB-FUBINACA is a cannabinoid receptor agonist with a synthetic indabole structure. Ki values at CB1 are 10.04 nM and 0.786 nM, respectively, and EC50 values are 0.5433 nM at CB1 and 0.12278 nM at CB2. It is marketed as a synthetic drug on the internet.




    MAB-CHMINACA is an indazole-based synthetic cannabinoid (CB) structurally similar to AB-CHMINACA, both of which have been found in herbal blend products and are classified as Schedule I substances by the US Drug Enforc…



  • mmb chminaca

    mmb chminaca


    mmb chminaca, also spelled MMB-CHMINACA, is an indole-based synthetic cannabinoid that has been sold as a designer drug on the internet. It is a potent CB1 receptor agonist.


  • nm 2201

    nm 2201


    nm 2201, also known as CBL-2201, is an indole-based synthetic cannabinoid that has the same effects as the closely related 5F-PB-22 and NNE1, which are both full agonists with low nanomolar affinity for CB1 and CB2 receptors.